Additional file 1 of Novel enzyme-linked aptamer-antibody sandwich assay and hybrid lateral flow strip for SARS-CoV-2 detection

Additional file 1: Table S1. Comparison of commercial antibodies specific SARS-CoV-2 N protein using iELISA. Table S2. Comparison of commercial ELISA kit for SARS-CoV-2 antigen detection. Table S3. Comparison of commercial rapid test strip for SARS-CoV-2 antigen detection. Table S4. Performance indicators of hybrid lateral flow strip for infected and healthy volunteers. Fig. S1. Western blotting analysis of expression SARS-CoV-2 N protein using commercial anti-SARS-CoV-2 N protein antibodies. Fig. S2. The stability analysis of (A) the hybrid ELAAA was conducted throughout its storage period under 4 °C. The results represent the mean ± SD of absorbance value obtained from three independent replicates. (B-C) the hybrid-LFS was conducted throughout its storage period under vacuum packaging. The results represent the mean ± SD of test line intensity (RLU) obtained from three independent replicates. Fig. S3. Optimization of the Hybrid-LFA. (A) Comparison of the pH value of conjugation buffer. Hybrid-LFA conditions include 20 nm gold nanoparticles with 150 µg of mAb in this evaluation. (B) Comparison of the particle size of the gold nanoparticle. This assessment involves conjugation buffer (pH 5.5) and 150 µg of mAb under hybrid-LFA conditions. (C) Comparison of the quantity of antibodies on the surfaces of gold nanoparticles. The examination is conducted using conjugation buffer (pH 5.5) and 40 nm gold nanoparticles within hybrid-LFA settings. All compared groups utilize samples containing 100 ng/mL SARS-CoV-2 N protein and 0 ng/mL SARS-CoV-2 N protein.